Genesis Molecular AI Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 170

Employees

  • Latest Deal Type
  • Later Stage VC
  • (Announced)

  • Latest Deal Amount
  • $120M

  • Investors
  • 23

Genesis Molecular AI General Information

Description

Developer of artificial intelligence-driven drug discovery technology designed to accelerate the identification and development of small molecule medicines. The company's technology integrates generative AI models with computational chemistry and iterative, interdisciplinary research workflows to design, evaluate, and optimize small molecule drug that drives the discovery and development of novel molecule drugs to treat patients suffering from severe and debilitating diseases, enabling the medical community to upgrade and optimize patient clinical outcomes.

Contact Information

Website
www.genesis.ml
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 South Ellsworth Avenue
  • Suite 450
  • San Mateo, CA
  • United States
+1 (203)
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Corporate Office
  • 101 South Ellsworth Avenue
  • Suite 450
  • San Mateo, CA
  • United States
+1 (203)

Genesis Molecular AI Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genesis Molecular AI Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 20-May-2026 $120M Announced Generating Revenue
5. Later Stage VC 13-Nov-2024 Completed Generating Revenue
4. Early Stage VC (Series B) 25-Aug-2023 Completed Generating Revenue
3. Early Stage VC (Series A2) 26-Aug-2022 Completed Generating Revenue
2. Early Stage VC (Series A) 24-Nov-2020 $52M $56.1M Completed Generating Revenue
1. Seed Round 22-Apr-2019 $4.1M $4.1M Completed Startup
To view Genesis Molecular AI’s complete valuation and funding history, request access »

Genesis Molecular AI Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series B
Series A-2
Series A-1
Series A 9,254,372 $0.000010 $0.31 $5.11 $5.11 1x $5.11 11.15%
Seed 4,485,796 $0.000010 $0.06 $0.92 $0.92 1x $0.92 5.4%
To view Genesis Molecular AI’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Genesis Molecular AI Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of artificial intelligence-driven drug discovery technology designed to accelerate the identification and deve
Drug Discovery
San Mateo, CA
170 As of 2026

South San Francisco, CA
 

Oxford, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genesis Molecular AI Competitors (11)

One of Genesis Molecular AI’s 11 competitors is X-37, a Venture Capital-Backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
X-37 Venture Capital-Backed South San Francisco, CA
Exscientia Formerly VC-backed Oxford, United Kingdom
NuMedii Formerly VC-backed San Mateo, CA
Numerion Labs Venture Capital-Backed San Francisco, CA
Verge Labs Venture Capital-Backed San Francisco, CA
You’re viewing 5 of 11 competitors. Get the full list »

Genesis Molecular AI Patents

Genesis Molecular AI Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026096998-A1 Generating predicted 3d structures of molecular systems using generative models with equivariant attention layers Pending 01-Nov-2024
WO-2026024674-A1 Methods of treating skp2-associated cancers Pending 22-Jul-2024
WO-2025179257-A1 Generative machine learning models for protein-ligand docking Pending 23-Feb-2024
WO-2025179253-A1 Training generative machine learning models for 3d molecular structure prediction using alignment objectives Pending 23-Feb-2024
WO-2025144931-A1 Methods for treating cancer Inactive 27-Dec-2023 C07D471/04
To view Genesis Molecular AI’s complete patent history, request access »

Genesis Molecular AI Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genesis Molecular AI Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
Valera Capital Family Office Minority
Baker Brothers Investments Hedge Fund Minority
BlackRock Asset Manager Minority
Fidelity Management & Research Company Asset Manager Minority
Lilly USA Corporation Minority
You’re viewing 5 of 23 investors. Get the full list »

Genesis Molecular AI FAQs

  • When was Genesis Molecular AI founded?

    Genesis Molecular AI was founded in 2019.

  • Where is Genesis Molecular AI headquartered?

    Genesis Molecular AI is headquartered in San Mateo, CA.

  • What is the size of Genesis Molecular AI?

    Genesis Molecular AI has 170 total employees.

  • What industry is Genesis Molecular AI in?

    Genesis Molecular AI’s primary industry is Drug Discovery.

  • Is Genesis Molecular AI a private or public company?

    Genesis Molecular AI is a Private company.

  • What is Genesis Molecular AI’s current revenue?

    The current revenue for Genesis Molecular AI is .

  • How much funding has Genesis Molecular AI raised over time?

    Genesis Molecular AI has raised $327M.

  • Who are Genesis Molecular AI’s investors?

    Valera Capital, Baker Brothers Investments, BlackRock, Fidelity Management & Research Company, and Lilly USA are 5 of 23 investors who have invested in Genesis Molecular AI.

  • Who are Genesis Molecular AI’s competitors?

    X-37, Exscientia, NuMedii, Numerion Labs, and Verge Labs are some of the 11 competitors of Genesis Molecular AI.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process